Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

New non-amphetaminic ADHD drug ‘speeds’ into Phase II


Narcolepsy drug gets Chinese approval

Trial and new drug for Tourette Syndrome after $250M after funding round completed

The top psychedelic drug developers leading the market

Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

Get to Know the Top 50 Women in the UK’s Biotech Scene

Shire’s Adderall alternative granted EMA approval for EU